G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy
Poorva Bindal(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Carolyn D. Alonso(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), David Sermer, Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Michael Leukam(Beth Israel Deaconess Medical Center), Laura E. Dodge(Beth Israel Deaconess Medical Center), Pavania Elavalakanar(Beth Israel Deaconess Medical Center), Emma Logan(Beth Israel Deaconess Medical Center), Matthew Weinstock(Beth Israel Deaconess Medical Center), Jessica Liegel(Beth Israel Deaconess Medical Center), Caitlin A. Trottier(Tufts University)
Cited by 4
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k